FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Recli Federico Seghi

2. Date of Event Requiring Statement (MM/DD/YYYY)
5/14/2018 

3. Issuer Name and Ticker or Trading Symbol

TITAN PHARMACEUTICALS INC [TTNP]

(Last)        (First)        (Middle)

VIA ILIO BARONTINI 8

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                            _____ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

SCANDICCI (FLORENCE), L6 50018       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   100845   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (Right to Buy)     (1) 5/14/2028   Common Stock   5000   $0.84   D    
Convertible Note   3/21/2018   6/1/2021   Common Stock   2000000   (2) $1.20   I   See footnote   (2)
Warrant (Right to Buy)   3/21/2018   3/21/2025   Common Stock   540000   (2) $1.20   I   See footnote   (2)

Explanation of Responses:
(1)  Vests in 12 equal monthly installments commencing on the date of grant.
(2)  Reflects shares underlying securities held by L. Molteni & C. Dei Frattelli Alitti Societa Di Esercizio S.P.A. Mr. Seghi Recli does not have voting or dispositive power over, and disclaims beneficial ownership of, such underlying shares, except to the extent of his direct pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Recli Federico Seghi
VIA ILIO BARONTINI 8
SCANDICCI (FLORENCE), L6 50018 		X



Signatures
/s/ Federico Seghi Recli 5/23/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Titan Pharmaceuticals Charts.
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Titan Pharmaceuticals Charts.